- Amplifon’s second quarter net revenue was €592.7 million, falling short of the estimated €629.6 million.
- In the EMEA region, Amplifon reported revenue of €382.4 million, below the anticipated €403.7 million.
- The APAC region saw revenues of €85.7 million, slightly under the estimated €90 million.
- Revenue from the Americas amounted to €124.6 million, missing the expectation of €132.9 million.
- Analyst recommendations for Amplifon include 12 buys, 6 holds, and 1 sell.
A look at Amplifon SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Amplifon SpA, a company specializing in retailing and fitting hearing aids along with related services, is positioned with a promising long-term outlook according to Smartkarma Smart Scores. With a momentum score of 4, indicating strong positive market momentum, Amplifon shows potential for continued growth and performance. The company also demonstrates resilience with a score of 3, suggesting its ability to weather challenges and maintain stability over time. Moreover, the growth score of 3 highlights the potential for future expansion and development within its industry.
Although Amplifon’s value and dividend scores are at 2, indicating moderate performance in these areas, the overall outlook remains positive. Amplifon S.p.A. operates across multiple countries, including Italy, France, Spain, and the United States, through a network of distribution centers and licensee partners. With a solid foundation and favorable momentum, Amplifon SpA appears well-positioned for long-term success in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
